Seres Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $23.59M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | Before market open | – | $3.75 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Seres Therapeutics filed with the SEC
SERES THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES, INCLUDING
Results of operations · EX-99.1 to Form 8-K
SERES THERAPEUTICS ANNOUNCES EARLY CLINICAL DATA SHOWING POTENTIAL FOR
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Seres Company Overview July 2026 Seres
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
SERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Seres Company Overview March 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SERES THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Presentation November 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Presentation August 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Presentation May 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Seres Therapeutics Investor Presentation March 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimers Forward Looking Statements This communication contains
Regulation FD disclosure · EX-99.1 to Form 8-K
Seres Therapeutics Announces New Translational Biomarker Results from SER-155
Results of operations · Other events · EX-99.1 to Form 8-K
SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND
Results of operations · Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Presentation November 13, 2024 Exhibit 99.2
Results of operations · Listing notice · Regulation FD disclosure · EX-99.2 to Form 8-K
Seres Therapeutics Announces Completion of VOWST Asset Sale to
Material agreement · Agreement terminated · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Unaudited Pro Forma Combined Financial Information
Material agreement · Agreement terminated · Acquisition or disposition completed · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Disclaimers Forward Looking Statements This communication contains
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Disclaimers Forward Looking Statements This communication contains
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Regulation FD disclosure · EX-99.1 to Form 8-K
SERES THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Presentation August 13, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SERES THERAPEUTICS ANNOUNCES SIGNING OF VOWST™ ASSET PURCHASE AGREEMENT WITH NESTLÉ HEALTH SCIENCE
Regulation FD disclosure · EX-99.1 to Form 8-K
SERES THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Results of operations · EX-99.1 to Form 8-K
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business
Results of operations · EX-99.1 to Form 8-K
SERES THERAPEUTICS ANNOUNCES THE APPOINTMENT OF MARELLA THORELL AS CHIEF FINANCIAL OFFICER AND THE RETIREMENT OF DAVID
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Seres Therapeutics Announces VOWST Commercial
Results of operations · EX-99.1 to Form 8-K
Therapeutics Investor Presentation Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST Net Sales of $7.6 Million
Results of operations · EX-99.1 to Form 8-K
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements Some of the statements in this presentation
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Some of the statements in this
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SER-155 Phase 1b Cohort 1 Day 100 Data
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Forward Looking Statements Some of the statements in this presentation
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K